Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database

Introduction: Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Methods: Patient-level data...

Descripción completa

Detalles Bibliográficos
Autores: Muller-Wieland, D, Freemantle, N, Bonadonna, RC, Mauquoi, C, Bigot, G, Bonnemaire, M, Gourdy, P, Mauricio, D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p15422
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15422
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145509001&doi=10.1007%2fs13300-022-01356-3&partnerID=40&md5=a27ae01020b016dc5844a3bd978ef8c7
Access Level:acceso abierto
Palabra clave:Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
id ES_4d62e63d093c873dab899474cb5b5b76
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p15422
network_acronym_str ES
network_name_str España
repository_id_str
spelling Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled DatabaseMuller-Wieland, DFreemantle, NBonadonna, RCMauquoi, CBigot, GBonnemaire, MGourdy, PMauricio, DBasal insulin analoguesBasal insulin switchingInsulin glargine 300 U/mlNeutral protamine Hagedorn insulinPooled databaseRoutine clinical practiceType 2 diabetes mellitusIntroduction: Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Methods: Patient-level data were pooled from 11 prospective, open-label, 24-week studies. Participants were classified according to the type of prior BI. Of the 4463 participants, 1282 (28.7%) were pre-treated with neutral protamine Hagedorn (NPH) insulin and 2899 (65.0%) with BI analogues (BIAs), and 282 (6.3%) had undetermined prior BI. Results: There were no meaningful differences in baseline characteristics between subgroups, except for a higher prevalence of diabetic neuropathy in the NPH subgroup (21.6% versus 7.8% with BIAs). Mean +/- standard deviation haemoglobin A1c (HbA1c) decreased from 8.73 +/- 1.15% and 8.35 +/- 0.95% at baseline to 7.71 +/- 1.09% and 7.82 +/- 1.06% at week 24 in the NPH and BIA subgroups, respectively. Least squares (LS) mean change in HbA1c was -0.85% (95% confidence interval -0.94 to -0.77) in NPH subgroup and -0.70% (- 0.77 to -0.64) in BIA subgroup, with a LS mean absolute difference between subgroups of 0.16 (0.06-0.26; p = 0.002). Gla-300 mean daily dose was slightly increased at week 24 by 0.07 U/kg/day (approximately 6 U/day) in both subgroups. Incidences of symptomatic and severe hypoglycaemia were low, without body weight change. Conclusions: Irrespective of previous BI therapy (NPH insulin or BIAs), switching to Gla-300 improved glycaemic control without weight gain and with low symptomatic and severe hypoglycaemia incidences. However, a slightly greater glucose-lowering effectiveness was observed in people pre-treated with NPH insulin.SPRINGER HEIDELBERG2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15422https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145509001&doi=10.1007%2fs13300-022-01356-3&partnerID=40&md5=a27ae01020b016dc5844a3bd978ef8c7Diabetes TherapyISSN: 18696953ISSNe: 18696961reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p154222026-06-14T12:41:47Z
dc.title.none.fl_str_mv Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
title Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
spellingShingle Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Muller-Wieland, D
Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
title_short Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
title_full Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
title_fullStr Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
title_full_unstemmed Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
title_sort Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
dc.creator.none.fl_str_mv Muller-Wieland, D
Freemantle, N
Bonadonna, RC
Mauquoi, C
Bigot, G
Bonnemaire, M
Gourdy, P
Mauricio, D
author Muller-Wieland, D
author_facet Muller-Wieland, D
Freemantle, N
Bonadonna, RC
Mauquoi, C
Bigot, G
Bonnemaire, M
Gourdy, P
Mauricio, D
author_role author
author2 Freemantle, N
Bonadonna, RC
Mauquoi, C
Bigot, G
Bonnemaire, M
Gourdy, P
Mauricio, D
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
topic Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
description Introduction: Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Methods: Patient-level data were pooled from 11 prospective, open-label, 24-week studies. Participants were classified according to the type of prior BI. Of the 4463 participants, 1282 (28.7%) were pre-treated with neutral protamine Hagedorn (NPH) insulin and 2899 (65.0%) with BI analogues (BIAs), and 282 (6.3%) had undetermined prior BI. Results: There were no meaningful differences in baseline characteristics between subgroups, except for a higher prevalence of diabetic neuropathy in the NPH subgroup (21.6% versus 7.8% with BIAs). Mean +/- standard deviation haemoglobin A1c (HbA1c) decreased from 8.73 +/- 1.15% and 8.35 +/- 0.95% at baseline to 7.71 +/- 1.09% and 7.82 +/- 1.06% at week 24 in the NPH and BIA subgroups, respectively. Least squares (LS) mean change in HbA1c was -0.85% (95% confidence interval -0.94 to -0.77) in NPH subgroup and -0.70% (- 0.77 to -0.64) in BIA subgroup, with a LS mean absolute difference between subgroups of 0.16 (0.06-0.26; p = 0.002). Gla-300 mean daily dose was slightly increased at week 24 by 0.07 U/kg/day (approximately 6 U/day) in both subgroups. Incidences of symptomatic and severe hypoglycaemia were low, without body weight change. Conclusions: Irrespective of previous BI therapy (NPH insulin or BIAs), switching to Gla-300 improved glycaemic control without weight gain and with low symptomatic and severe hypoglycaemia incidences. However, a slightly greater glucose-lowering effectiveness was observed in people pre-treated with NPH insulin.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15422
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145509001&doi=10.1007%2fs13300-022-01356-3&partnerID=40&md5=a27ae01020b016dc5844a3bd978ef8c7
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15422
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145509001&doi=10.1007%2fs13300-022-01356-3&partnerID=40&md5=a27ae01020b016dc5844a3bd978ef8c7
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER HEIDELBERG
publisher.none.fl_str_mv SPRINGER HEIDELBERG
dc.source.none.fl_str_mv Diabetes Therapy
ISSN: 18696953
ISSNe: 18696961
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407688210776064
score 15,812429

Similares en LA Referencia